181 related articles for article (PubMed ID: 29621877)
1. The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH.
Liang JH; Lu L; Zhu HY; Li W; Fan L; Li JY; Xu W
Cancer Res Treat; 2019 Jan; 51(1):150-157. PubMed ID: 29621877
[TBL] [Abstract][Full Text] [Related]
2. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Yang QX; Pei XJ; Tian XY; Li Y; Li Z
Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
[TBL] [Abstract][Full Text] [Related]
3. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma.
Eladl AE; Shimada K; Suzuki Y; Takahara T; Kato S; Kohno K; Elsayed AA; Wu CC; Tokunaga T; Kinoshita T; Sakata-Yanagimoto M; Nakamura S; Satou A
Cancer Med; 2020 Jan; 9(2):678-688. PubMed ID: 31793218
[TBL] [Abstract][Full Text] [Related]
4. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Ramos JC; Sparano JA; Chadburn A; Reid EG; Ambinder RF; Siegel ER; Moore PC; Rubinstein PG; Durand CM; Cesarman E; Aboulafia D; Baiocchi R; Ratner L; Kaplan L; Capoferri AA; Lee JY; Mitsuyasu R; Noy A
Blood; 2020 Sep; 136(11):1284-1297. PubMed ID: 32430507
[TBL] [Abstract][Full Text] [Related]
5. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
8. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S; Kosugi-Kanaya M; Shigematsu A; Kobayashi H; Yamamoto S; Kobayashi N; Iwasaki H; Mori A; Kunieda Y; Yutaka T; Kurosawa M; Kakinoki Y; Endo T; Kondo T; Hashino S; Teshima T;
Leuk Lymphoma; 2015; 56(9):2592-7. PubMed ID: 25563559
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
10. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
11. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
13. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
14. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features.
Lee WJ; Won KH; Choi JW; Won CH; Chang SE; Choi JH; Lee MW
J Am Acad Dermatol; 2019 Oct; 81(4):989-997. PubMed ID: 30240776
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma.
Poon F; Ieremia E; Collins G; Matin RN
Am J Dermatopathol; 2019 Dec; 41(12):927-930. PubMed ID: 31599749
[TBL] [Abstract][Full Text] [Related]
17. Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma.
Chan TSY; Ip AHW; Au-Yeung R; Pang AWK; Kwong YL
Ann Hematol; 2020 Dec; 99(12):2949-2952. PubMed ID: 32514627
[No Abstract] [Full Text] [Related]
18. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
Kanakry JA; Li H; Gellert LL; Lemas MV; Hsieh WS; Hong F; Tan KL; Gascoyne RD; Gordon LI; Fisher RI; Bartlett NL; Stiff P; Cheson BD; Advani R; Miller TP; Kahl BS; Horning SJ; Ambinder RF
Blood; 2013 May; 121(18):3547-53. PubMed ID: 23386127
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.
Park JH; Yoon DH; Kim S; Park JS; Park CS; Sung H; Lee SW; Huh J; Suh C
Ann Hematol; 2016 Apr; 95(5):801-8. PubMed ID: 26883027
[TBL] [Abstract][Full Text] [Related]
20. High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi.
Montgomery ND; Randall C; Painschab M; Seguin R; Kaimila B; Kasonkanji E; Zuze T; Krysiak R; Sanders MK; Elliott A; Miller MB; Kampani C; Chimzimu F; Mulenga M; Damania B; Tomoka T; Fedoriw Y; Dittmer DP; Gopal S
Cancer Med; 2020 Jan; 9(2):552-561. PubMed ID: 31782984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
